Cancer and Aging Resilience Evaluation in Older Adults With Hematologic Malignancies: The CARE-Heme Registry

Multiple Myeloma Clinical Trial

— CARE-Heme  

Official title:

Cancer and Aging Resilience Evaluation in Older Adults With Hematologic Malignancies: The CARE-Heme Registry

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05556928
• Other study ID #: IRB-300005372
• Status: Recruiting
• Start date: July 21, 2020
• Est. completion date: December 31, 2024

Study information

• Verified date: February 2024
• Source: University of Alabama at Birmingham
• Contact: Smith Giri, Dr.
• Phone: (205) 638-2120
• Email: CAREheme[@]peds.uab.edu
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

The primary purpose of this protocol is to create a registry of older (≥50 years old) patients with Hematologic Malignancies. Our main objectives include: To understand the prevalence of frailty and geriatric impairments among patients aged ≥50y and above diagnosed with a hematologic malignancy at UAB and to gather information that would lend support for future research in this vulnerable population.

Description:

All participants will be invited to participate in a patient reported geriatric assessment questionnaire as well as an objective physical function testing. This includes the Short Physical Performance Battery (SPPB) that evaluates lower extremity performance and muscle strength assessment via hand grip dynamometer. Participants will also complete a 12 item modified version of PRO-CTCAE. This will be administered by trained research staff at the time of study enrollment. Repeat CARE instruments (Follow-up GA questionnaire and Physical Function test) will be administered after the baseline visit to measure changes in patient reported outcomes at 3 months, 6 months, and one year. A one-time blood or saliva sample will be requested and obtained at baseline or a follow-up visit.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 5000
• Est. completion date: December 31, 2024
• Est. primary completion date: December 31, 2024
• Gender: All
• Age group: 50 Years and older

Eligibility

Inclusion Criteria:

• Patients are =50 years of age.

• Patients have a biopsy proven diagnosis of Hematologic Malignancy (Multiple Myeloma, AL Amyloidosis, Waldenstrom's Macrogloblunemia, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Myelodysplastic syndromes, Myeloproliferative Neoplasm, Acute/Chronic Myeloid Leukemia, Acute/Chronic Lymphoid Leukemia).

• Patients have appointments at UAB including if they are an inpatient or other clinic locations.

Exclusion Criteria:

• Individuals who are <50 years old.

• Patients who do not read and/or speak English will not be eligible for this study as many of the questionnaires are not validated in other languages. No exclusions will be made based on gender, ethnicity or race.

Related Conditions & MeSH terms

• Amyloidosis
• Hematologic Neoplasms
• Leukemia, Plasma Cell
• Multiple Myeloma
• Plasma Cell Leukemia

Locations

Country	Name	City	State
United States	Kirklin Clinic of UAB Hospital	Birmingham	Alabama

Sponsors (1)

Lead Sponsor	Collaborator
University of Alabama at Birmingham

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Create the CARE-Heme Registry	To establish and maintain a well-annotated registry (to be called the 'CARE-Heme' Registry) of adults =50 years of age with a hematologic malignancy to improve our understanding of this vulnerable population.	5 years
Secondary	To administer a patient reported geriatric assessment and a brief objective physical assessment.	To measure the proportion of patients with overall and domain-specific geriatric impairments, the proportion of patients with Myopenia, and the proportion of patients with frailty.	5 years